Biogen’s headquarters on Binney Street on Thursday, March 21, 2019 in Cambridge, Massachusetts.
Nikolai Charnetsky MediaNews Group | Getty Images
Significant approval of Biogen’s Alzheimer’s drug should be a big winner for the company, even if the treatment is used by only a small percentage of patients, according to investment company Cowen.
Shares of the company rose 38% on Monday after approval of the drug, named Aduhelm.
As stocks improved to outperform market indicators, Cowen analyst Phil Nado said in an investor̵